PSNL (Personalis) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PSNL Personalis Inc PSNL
59 GF Score
Price $15.55
GF Value $2.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Personalis 5-Year Yield-on-Cost %?

Personalis PSNL -1.55% 59 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus rates PSNL with a GF Score™ of 59/100 and a GF Value™ of $2.08 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Personalis ranks worse than 1562498.44% on this metric.

Personalis's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Personalis's 5-Year Yield-on-Cost % or its related term are showing as below:



PSNL's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.455
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Personalis  (NAS:PSNL) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Personalis 5-Year Yield-on-Cost % Related Terms


PSNL vs CDNA, OPK, NEO: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Personalis's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Personalis's 5-Year Yield-on-Cost % falls into.


PSNL
59GF Score
Personalis Inc PSNL
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Personalis 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Personalis is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Personalis (PSNL) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Personalis and its competitors. According to the industry distribution chart, Personalis ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Personalis' 5-Year Yield-on-Cost % too high?
Personalis' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Personalis ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Personalis has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Personalis' 5-Year Yield-on-Cost % compare to CDNA and OPK?
According to the Medical Diagnostics & Research industry distribution chart, Personalis ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places Personalis in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.46, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Personalis and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Personalis's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Personalis stock overvalued right now?
Based on GuruFocus' analysis, Personalis (PSNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.08, compared to a current price of $15.55 — trading 647.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Personalis' overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Personalis (PSNL), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Personalis (PSNL) Overvalued in 2026?

Based on GuruFocus' analysis, Personalis stock appears to be overvalued. The current stock price of $15.55 is trading 647.4% above its estimated GF Value™ of $2.08. GuruFocus considers Personalis to be Significantly Overvalued.

Key valuation signals for PSNL:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $2.08 vs. price of $15.55 (647.4% above fair value)
  • GF Score™: 59/100 with 9 warning signs

No single metric tells the full story. See the PSNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Personalis Business Description

Other Exchanges 04X:Germany
Address 6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
59GF Score

Get the complete analysis for PSNL

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.55
Price
$2.08
GF Value